References
- EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies). 2016. Scientific opinion on dietary reference values for choline. EFSA J. 2016;14(8):4484.
- Chand RR, Nimick M, Cridge B, et al. In vitro hepatic assessment of cineole and its derivatives in common brushtail possums (Trichosurus vulpecula) and rodents. Biology. 2021;10(12):1326.
- Sevrioukova IF, Poulos TL. Understanding the mechanism of cytochrome P450 3A4: recent advances and remaining problems. Dalton Trans. 2013;42(9):3116–3126.
- Linn CE, Shah NK, Epstein BJ. Role of CYP450 in antiplatelet therapy: considerations for patients at risk for further cardiovascular or cerebrovascular problems. J PharmacyTechnol. 2013;29(2):72–87.
- Molden E. Variability in cytochrome P450-mediated metabolism of cardiovascular drugs: clinical implications and practical attempts to avoid potential problems. Heart Drug. 2004;4(2):55–79.
- Colburn DE, Giles FJ, Oladovich D, et al. In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Hematology. 2004;9(3):217–221.
- Ekroos M, Sjögren T. Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc Natl Acad Sci U S A. 2006;103(37):13682–13687.
- Gao X, Jiang C, Xu J, et al. Serum pharmacokinetics of choline, trimethylamine, and trimethylamine-N-oxide after oral gavage of phosphatidylcholines with different fatty acid compositions in mice. Biosci Biotechnol Biochem. 2016;80(11):2217–2223.
- Hayes C, Ansbro D, Kontoyianni M. Elucidating substrate promiscuity in the human cytochrome 3A4. J Chem Inf Model. 2014;54(3):857–869.
- Li X, Xu Y, Lai L, et al. Prediction of human cytochrome P450 inhibition using a multitask deep autoencoder neural network. Mol Pharm. 2018;15(10):4336–4345.
- Wang A, Stout CD, Zhang Q, et al. Contributions of ionic interactions and protein dynamics to cytochrome P450 2D6 (CYP2D6) substrate and inhibitor binding. J Biol Chem. 2015;290(8):5092–5104.
- Marechal J-D, Yu J, Brown S, et al. In silico and in vitro screening for inhibition of cytochrome p450 CYP3A4 by comedications commonly used by patients with cancer. Drug Metab Dispos. 2006;34(4):534–538.
- Olsen L, Oostenbrink C, Jorgensen F. Prediction of cytochrome P450 mediated metabolism. Adv Drug Deliv Rev. 2015;86:61–71.
- Pang X, Zhang B, Mu G, et al. Screening of cytochrome P450 3A4 inhibitors via in silico and in vitro approaches. RSC Adv. 2018;8(61):34783–34792.
- Ridhwan MJM, Bakar SIA, Latip NA, et al. A comprehensive analysis of human CYP3A4 crystal structures as a potential tool for molecular docking-based site of metabolism and enzyme inhibition studies. J Comput Biophys Chem. 2022;21(03):259–285.
- Sansen S, Yano JK, Reynald RL, et al. Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2. J Biol Chem. 2007;282(19):14348–14355.
- Sevrioukova IF, Poulos TL. Structural basis for regiospecific midazolam oxidation by human cytochrome P450 3A4. Proc Natl Acad Sci U S A. 2017;114(3):486–491.
- Wiedeman AM, Barr SI, Green TJ, et al. Dietary choline intake: current state of knowledge across the life cycle. Nutrients. 2018;10(10):1513.
- Yim S-K, Kim K, Chun S, et al. Screening of human CYP1A2 and CYP3A4 inhibitors from seaweed in silico and in vitro. Mar Drugs. 2020;18(12):603.
- Zeisel SH. Choline: critical role during fetal development and dietary requirements in adults. Annu Rev Nutr. 2006;26:229–250.